Sign Out
VARILRIX is contraindicated in subjects with severe humoral or cellular immunodeficiency such as: Subjects with primary or acquired immunodeficiency states with a total lymphocyte count less than 1,200 per mm3; Subjects presenting other evidence of lack of cellular immune competence (e.g. subjects with leukaemias, lymphomas, blood dyscrasias, clinically manifest HIV infection); Subjects receiving immunosuppressive therapy including high dose of corticosteroids.
See also Precautions.
VARILRIX is contraindicated in subjects with known hypersensitivity to neomycin or to any other component of the vaccine. A history of contact dermatitis to neomycin is not a contraindication.
VARILRIX is contraindicated in subjects having shown signs of hypersensitivity after previous administration of varicella vaccine.
VARILRIX is contraindicated in pregnant women. Pregnancy should be avoided for one month after vaccination (see Use in Pregnancy & Lactation).
